promising treatment for severe post-COVID syndrome in children using celiac disease drug
A groundbreaking study reveals that an experimental drug for celiac disease shows promise in treating severe post-COVID syndrome in children, offering new hope for MIS-C recovery.
Recent research from Mass General Brigham has revealed that an experimental drug originally designed to treat celiac disease shows potential in managing severe post-COVID syndrome, particularly MIS-C, in children. MIS-C is a rare but serious condition that can develop after a COVID-19 infection, characterized by high fever, gastrointestinal symptoms, and potentially life-threatening heart complications. In a small yet significant trial, the oral drug larazotide was administered to children with early-stage MIS-C, demonstrating safety and promising efficacy.
The double-blind, randomized study involved 12 children who received either a placebo or larazotide four times daily over 21 days, with a follow-up period of six months. Results indicated that children treated with larazotide experienced faster resolution of gastrointestinal symptoms, quicker clearance of viral particles, and a rapid return to normal activities. The mechanism involves larazotide strengthening the intestinal barrier, which limits the exit of SARS-CoV-2 viral particles from the gut into the bloodstream, potentially reducing systemic inflammation.
Led by Dr. Lael Yonker, the study's findings are published in Science Translational Medicine and suggest that larazotide could be a safe and effective treatment option for MIS-C. The promising results have encouraged further investigation into larazotide’s role in treating long COVID. Current treatments for MIS-C mainly involve anti-inflammatory drugs, but many patients experience symptom rebound, underscoring the need for targeted therapies like larazotide. Researchers are now conducting larger trials to determine whether this approach can be extended to broader populations, including those suffering from long COVID, with hopes of improving recovery times and overall outcomes.
source: https://medicalxpress.com/news/2025-07-drug-celiac-disease-severe-covid.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Most Americans Recognize Plasma Donation as a Life-Saving Practice But Participation Remains Low
A recent survey uncovers that while most Americans recognize the life-saving potential of plasma donation, actual participation remains low, highlighting the need for increased awareness and education during International Plasma Awareness Week.
Innovative Approaches to Combat Kidney Disease by Targeting Neutrophils
Emerging research reveals how targeted therapies against neutrophils and NETs could revolutionize treatment for various kidney diseases, reducing inflammation and tissue damage.
President Trump Overstates Speed and Certainty of Prescription Drug Price Cuts
President Trump claimed an executive order would lead to nearly immediate reductions in prescription drug prices, but experts warn the process is complex and will take months or years. Learn about the implications and challenges of federal efforts to lower drug costs in the U.S.
Recall of Frozen Vegetables Across Six States Due to Listeria Contamination
Endico Potatoes Inc. has recalled frozen vegetables across six states due to potential Listeria contamination, cautioning consumers to return the products and avoid health risks.